Company intelligence / Profile preview

Sierra Oncology

San Mateo, California, United Statessierrahemonc.com ↗

Ownership: Private
Employees: ~109
Development stage: Phase 3

Overview

Sierra Oncology’s lead drug candidate, momelotinib, demonstrated positive topline results in the MOMENTUM Phase III trial for myelofibrosis. The study met all primary and key secondary endpoints including symptom reduction and transfusion independence. The company planned regulatory submissions based on these results prior to its acquisition by GSK.

Therapeutic areas: OncologyHematology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

momelotinib

Phase 3

Indications: Myelofibrosis

2 more assets in the full pipeline.

Request access →

Partnerships

AstraZeneca AB (in-license of AZD5153 BET inhibitor)Carna Biosciences, Inc. (license agreement for SRA141)CRT Pioneer Fund LPOther licensing partners for pipeline assets.

Beyond the preview

Go deeper on Sierra Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sierra Oncology.

Explore the full profile